ATE306473T1 - Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide - Google Patents

Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide

Info

Publication number
ATE306473T1
ATE306473T1 AT98965275T AT98965275T ATE306473T1 AT E306473 T1 ATE306473 T1 AT E306473T1 AT 98965275 T AT98965275 T AT 98965275T AT 98965275 T AT98965275 T AT 98965275T AT E306473 T1 ATE306473 T1 AT E306473T1
Authority
AT
Austria
Prior art keywords
alkene
alkine
carboxamide
production
well
Prior art date
Application number
AT98965275T
Other languages
English (en)
Inventor
Elfi Biedermann
Max Hasmann
Roland Loeser
Benno Rattel
Friedemann Reiter
Barbara Schein
Klaus Seibel
Klaus Vogt
Katja Wosikowski
Isabel Schemainda
Original Assignee
Klinge Co Chem Pharm Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinge Co Chem Pharm Fab filed Critical Klinge Co Chem Pharm Fab
Application granted granted Critical
Publication of ATE306473T1 publication Critical patent/ATE306473T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98965275T 1997-12-17 1998-12-16 Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide ATE306473T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19756236A DE19756236A1 (de) 1997-12-17 1997-12-17 Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
PCT/EP1998/008268 WO1999031063A1 (en) 1997-12-17 1998-12-16 New piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides

Publications (1)

Publication Number Publication Date
ATE306473T1 true ATE306473T1 (de) 2005-10-15

Family

ID=7852332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98965275T ATE306473T1 (de) 1997-12-17 1998-12-16 Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide

Country Status (9)

Country Link
EP (1) EP1060163B1 (de)
JP (2) JP4855576B2 (de)
AT (1) ATE306473T1 (de)
AU (1) AU2054399A (de)
DE (2) DE19756236A1 (de)
DK (1) DK1060163T3 (de)
ES (1) ES2251794T3 (de)
WO (1) WO1999031063A1 (de)
ZA (1) ZA9811235B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19756236A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
EP1031564A1 (de) 1999-02-26 2000-08-30 Klinge Pharma GmbH Hemmer der Nicotinamidmonononukleotide-Bildung und deren Verwendung zur Krebstherapie
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
EP1348434A1 (de) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Verwendung von Pyridylamiden als Inhibitoren von Angiogenese
WO2003099272A1 (en) 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
EP2098231A1 (de) * 2008-03-05 2009-09-09 Topotarget Switzerland SA Verwendung von NAD Synthesis Hemmern zur Behandlung von ischämischen Reperfusionsschäden
CN102186822A (zh) 2008-08-29 2011-09-14 顶标公司 新脲和硫脲衍生物
WO2010066709A1 (en) * 2008-12-09 2010-06-17 Topotarget A/S Novel pyridinyl acrylamide derivatives
EP2453883A1 (de) 2009-07-17 2012-05-23 Topo Target A/S Verfahren zur prognose des nutzens der verabreichung von nikotinsäure bzw. einem vorläufer oder prodrug daraus zur minderung des schweregrades der nebenwirkungen einer krebsbehandlung mit nikotinamid-phosphoribosyltransferase-hemmern
WO2012031197A1 (en) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Novel compounds and compositions for the inhibition of nampt
RU2593759C2 (ru) 2010-09-03 2016-08-10 ФОРМА ТиЭм, ЭлЭлСИ Гуанидиновые соединения и композиции для ингибирования nampt
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム, エルエルシー. 癌などの疾患の治療のためのnampt阻害剤としての4−{[(ピリジン−3−イル−メチル)アミノカルボニル]アミノ}ベンゼン−スルホン誘導体
CA2834746A1 (en) 2011-05-04 2012-11-08 Forma Tm, Llc Novel compounds and compositions for the inhibition of nampt
US9555039B2 (en) 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CN105705152B (zh) 2013-06-14 2021-07-09 阿卡玛拉疗法有限公司 基于脂质的铂化合物和纳米粒子
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質のインヒビター
MX382355B (es) 2015-04-10 2025-03-13 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
EP3356347A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3377481A1 (de) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituierte chinazolinverbindungen mit einer substituierten heterocyclischen gruppe und verfahren zur verwendung davon
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (de) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573954A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11130740B2 (en) 2017-04-25 2021-09-28 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1H-indene analogs and methods using same
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CA3093851A1 (en) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
CN109485646A (zh) * 2018-12-12 2019-03-19 中国药科大学 一种苯并噻唑醌类化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8005133A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
JPS57136518A (en) * 1981-02-18 1982-08-23 Eisai Co Ltd Immunoregulator
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
EP0750496A1 (de) * 1994-03-14 1997-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verwendung von lipoxygenase-hemmet als therapeutische und interventions- antikrebsmittel
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19756236A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide

Also Published As

Publication number Publication date
ZA9811235B (en) 1999-06-08
AU2054399A (en) 1999-07-05
JP4855576B2 (ja) 2012-01-18
EP1060163B1 (de) 2005-10-12
DE19756236A1 (de) 1999-07-01
ES2251794T3 (es) 2006-05-01
EP1060163A1 (de) 2000-12-20
WO1999031063A1 (en) 1999-06-24
JP2002508356A (ja) 2002-03-19
DE69831877T2 (de) 2006-07-27
DK1060163T3 (da) 2006-02-27
DE69831877D1 (en) 2006-02-23
JP2011251976A (ja) 2011-12-15

Similar Documents

Publication Publication Date Title
DE69831877D1 (en) Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide
PT1042291E (pt) Piridilalcano, alceno e alcino carboxamidas substituidas com arilo, uteis como agentes citostaticos e imunossupressores
PT923570E (pt) Amidas de acidos piridil-alcenoicos e piridil-alcinicos como agentes citostaticos e imunossupressivos
DK1042315T3 (da) Cyklisk imid-substitueret pyridylalkan, alken og alkin carboxamider nyttige som cytostatiske og immunosuppressive midler
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
IL96549A0 (en) Production of a biologically active protein
PT705100E (pt) Guanidinas substituidas terapeuticas
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
DK0934309T3 (da) Nye pyridylalkansyreamider som cytostatiske og immunosuppressive midler
DE69712900D1 (de) Nitratester von corticoid verbindungen und die therapeutische verwendungen davon
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
DE59409735D1 (de) ALKOXYALKYLCARBAMATE VON IMIDAZO[1,2-a]PYRIDINEN
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ATE188873T1 (de) Tris-platin-komplexe
ES2184300T3 (es) Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.
DE59206628D1 (en) Expression signalpeptid-freier staphylokinasen
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1060163

Country of ref document: EP

EEIH Change in the person of patent owner